The Effect of Vitamin D Supplementation on Markers of Lipid Levels in Patients with Nonalcoholic Fatty Liver

Document Type : Original Article (s)

Authors

1 Food Security Research Center AND Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran

2 PhD Candidate, Food Security Research Center AND Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran

3 Associate Professor, Food Security Research Center AND Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran

4 Associate Professor, Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

5 Assistant Professor, Food Security Research Center AND Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Nonalcoholic fatty liver is a very common chronic liver disease. Disease, gradually causes liver cirrhosis and eventually liver transplantation. In patients with fatty liver, disorders in lipid parameters exist. Purpose of this study was to investigate the effect of vitamin D supplementation on lipid parameters in patients with nonalcoholic fatty liver.Methods: In thisrandomized parallel clinical trial study, 60 patients with non-alcoholic fatty liver disease participated in the intervention and placebo groups. For 10 weeks, the intervention and placebo groups received capsules of 50,000 IU vitamin D or placebo, respectively. Lipid parameters were measured at the beginning and end of the study. Nonalcoholic fatty liver was diagnosed by ultrasound. Data were analyzed using analysis of covariance (ANCOVA) and ordinal regression tests.Findings: In intervention group, the serum vitamin D levels were significantly increased compared to the placebo group. Total cholesterol as well as low-density lipoprotein (LDL) significantly decreased in intervention group, too. The effect of vitamin D supplementation was not significant on other variables.Conclusion: Vitamin D supplementation can reduce total cholesterol and LDL in patients with nonalcoholic fatty liver. But more researches must be conducted with large sample sizes and strong designs to confirm these findings.

Keywords

References

  1. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2007; 25(8): 883-9.
  2. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006; 40(Suppl 1): S5-10.
  3. Blackburn GL, Mun EC. Effects of weight loss surgeries on liver disease. Semin Liver Dis 2004; 24(4): 371-9.
  4. Wang JT, Liu YL. Non-alcoholic fatty liver disease: the problems we are facing. Hepatobiliary Pancreat Dis Int 2003; 2(3): 334-7.
  5. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121(1): 91-100.
  6. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006; 45(4): 600-6.
  7. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38(4): 1008-17.
  8. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26(Suppl 1): S5-20.
  9. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005; 28(11): 2745-9.
  10. Cronk CE, Roche AF. Race- and sex-specific reference data for triceps and subscapular skinfolds and weight/stature. The American Journal of Clinical Nutrition 1982; 35(2): 347-54.
  11. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94(9): 2467-74.
  12. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357(3): 266-81.
  13. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117(4): 503-11.
  14. Parker J, Hashmi O, Dutton D, Mavrodaris A, Stranges S, Kandala NB, et al. Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis. Maturitas 2010; 65(3): 225-36.
  15. Wang L, Manson JE, Song Y, Sesso HD. Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med 2010; 152(5): 315-23.
  16. Mithal A, Wahl DA, Bonjour JP, Burckhardt P, Dawson-Hughes B, Eisman JA, et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int 2009; 20(11): 1807-20.
  17. Lee JH, O'Keefe JH, Bell D, Hensrud DD, Holick MF. Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol 2008; 52(24): 1949-56.
  18. Zittermann A, Schleithoff SS, Koerfer R. Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr 2005; 94(4): 483-92.
  19. Jorde R, Grimnes G. Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids. Prog Lipid Res 2011; 50(4): 303-12.
  20. Witham MD, Dove FJ, Sugden JA, Doney AS, Struthers AD. The effect of vitamin D replacement on markers of vascular health in stroke patients - a randomised controlled trial. Nutr Metab Cardiovasc Dis 2012; 22(10): 864-70.
  21. Maki KC, Rubin MR, Wong LG, McManus JF, Jensen CD, Lawless A. Effects of vitamin D supplementation on 25-hydroxyvitamin D, high-density lipoprotein cholesterol, and other cardiovascular disease risk markers in subjects with elevated waist circumference. Int J Food Sci Nutr 2011; 62(4): 318-27.
  22. Sai AJ, Gallagher JC, Fang X. Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor-alpha genotypes. Menopause 2011; 18(10): 1101-12.
  23. Yeksan M, Turk S, Polat M, Cigli A, Erdogan Y. Effects of 1,25 (OH)2D3 treatment on lipid levels in uremic hemodialysis patients. Int J Artif Organs 1992; 15(12): 704-7.
  24. Rajpathak SN, Xue X, Wassertheil-Smoller S, Van Horn L, Robinson JG, Liu S, et al. Effect of 5 y of calcium plus vitamin D supplementation on change in circulating lipids: results from the Women's Health Initiative. Am J Clin Nutr 2010; 91(4): 894-9.
  25. Wehmeier K, Beers A, Haas MJ, Wong NC, Steinmeyer A, Zugel U, et al. Inhibition of apolipoprotein AI gene expression by 1, 25-dihydroxyvitamin D3. Biochim Biophys Acta 2005; 1737(1): 16-26.
  26. Foroughi M, Maghsoudi Z, Ghiasvand R, Iraj B, Askari G. Effect of Vitamin D Supplementation on C-reactive Protein in Patients with Nonalcoholic Fatty Liver. Int J Prev Med 2014; 5(8): 969-75.
  27. Foroughi M, Maghsoudi Z, Khayyatzadeh S, Ghiasvand R, Askari Gh, Iraj B. Relationship between non-alcoholic fatty liver disease and inflammation in patients with non-alcoholic fatty liver. ABR; 2014: 717(13). [In Press].
  28. Foroughi M, Maghsoudi Z, Ghiasvand R, Esmaillzadeh A, Iraj B, Askari Gh, Adibi P. The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver (NAFLD)". Iran J Nurs Midwifery Res; 2014. [In Press].
Journal of Isfahan Medical School
Volume 33, Issue 326 - Serial Number 326
January and February 2015
Pages 267-274

Files

History

  • Receive Date: 31 December 2013
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics